Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Kaveh Karimzad"'
Autor:
Efstratios Koutroumpakis, Raphael E Steiner, Sairah Ahmed, Michael Wang, Loretta J. Nastoupil, Nicolas Palaskas, Catherine M. Claussen, Jason R. Westin, Paolo Strati, Anita Deswal, Chelsea C. Pinnix, Jose Banchs, Lei Feng, Elizabeth J. Shpall, Francisco Vega, Cristina Gutierrez, Kaveh Karimzad, Sattva S. Neelapu, Gabriela Rondon, Melody R. Becnel
Publikováno v:
Haematologica. 107:1555-1566
Standard of care (SOC) chimeric antigen receptor (CAR) T-cell therapies such as axicabtagene ciloleucel (axi-cel) and tisagenlecleucel (tisa-cel) are associated with multisystem toxicities. There is limited information available about cardiovascular
Autor:
Talha Ahmed, Konstantinos Marmagkiolis, Michelle Ploch, Jorge A. Irizarry-Caro, Atia Amatullah, Shyam Desai, Moez K. Aziz, Akshitha Yarrabothula, José Fossas-Espinosa, Efstratios Koutroumpakis, Saamir Hassan, Kaveh Karimzad, Peter Kim, Mehmet Cilingiroglu, Cezar Iliescu
Publikováno v:
Current Problems in Cardiology. 48:101435
Cardiovascular disease and cancer are the leading causes of death worldwide. With advent of novel and improved cancer therapies, a growing population of cancer patients with cardiac complications is seen. Taking this into consideration, the clinical
Autor:
Nicolas Palaskas, Cezar Iliescu, Dinu Valentin Balanescu, Salman Arain, K. Lance Gould, Saamir Hassan, Teodora Donisan, Peter Kim, Juan Lopez-Mattei, Daryl Sudasena, Kaveh Karimzad
Publikováno v:
Cardiovascular Toxicology. 19:382-387
The use of vascular endothelial growth factor inhibitors such as sorafenib is limited by a risk of severe cardiovascular toxicity. A 28-year-old man with acute myeloid leukemia treated with prednisone, tacrolimus, and sorafenib following stem cell tr
Autor:
Konstantinos Charitakis, Konstantinos Marmagkiolis, Nicolas Palaskas, Dinu Valentin Balanescu, Cezar Iliescu, Mehmet Cilingiroglu, Juan Lopez-Mattei, Kaveh Karimzad, Peter Kim, Teodora Donisan
Publikováno v:
Cardiology clinics. 37(4)
Comorbidities specific to the cardio-oncology population contribute to the challenges in the interventional management of patients with cancer and cardiovascular disease (CVD). Patients with cancer have generally been excluded from cardiovascular ran
Autor:
Juhee Song, Teodora Donisan, David Boone, Serban Balanescu, Nils P. Johnson, Abdul Hakeem, Tariq Dayah, Cezar Iliescu, Michelle T. Lee, Nicolas Palaskas Md, Jean-Bernard Durand, Peter Kim, Eric H. Yang, Joerg Herrmann, Juan Lopez-Mattei, Konstantinos Toutouzas, Kaveh Karimzad, Konstantinos Marmagkioli, Dinu Balanescu
Publikováno v:
JACC: Cardiovascular Interventions. 12:S17-S18
When oncological and coronary artery disease (CAD) coincide, complications occur. Percutaneous coronary intervention (PCI) with subsequent dual antiplatelet therapy often delays cancer therapy. Recent data favor fractional flow reserve (FFR) over qua
Autor:
Peter Kim, Ezequiel D. Muñoz Gonzalez, Cezar Iliescu, Konstantinos Marmagkiolis, Serban Balanescu, Lopez-Mattei Juan, Kaveh Karimzad, Juhee Song, William Ntim, Teodora Donisan, Dinu Valentin Balanescu, Mehmet Cilingiroglu, Nicolas Palaskas, Jean-Bernard Durand, Daniel Jipescu
Publikováno v:
Journal of the American College of Cardiology. 73:1291
Newer generation drug-eluting stents (DES) may allow for early discontinuation of dual antiplatelet therapy (DAPT). DAPT duration after PCI has not been validated in cancer patients. We aimed to describe the practices and outcomes regarding DAPT dura